FBIO vs. BOLT, CDXS, AGEN, ACHV, SGMO, IRWD, DOMH, CRIS, SABS, and MTEM
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Bolt Biotherapeutics (BOLT), Codexis (CDXS), Agenus (AGEN), Achieve Life Sciences (ACHV), Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Dominari (DOMH), Curis (CRIS), SAB Biotherapeutics (SABS), and Molecular Templates (MTEM). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs. Its Competitors
Bolt Biotherapeutics (NASDAQ:BOLT) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
Bolt Biotherapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.
Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Fortress Biotech is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bolt Biotherapeutics had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Bolt Biotherapeutics and 2 mentions for Fortress Biotech. Bolt Biotherapeutics' average media sentiment score of 1.29 beat Fortress Biotech's score of 0.94 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.
Fortress Biotech received 247 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 63.69% of users gave Fortress Biotech an outperform vote while only 63.28% of users gave Bolt Biotherapeutics an outperform vote.
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 6.1% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 27.9% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Fortress Biotech has a net margin of -84.53% compared to Bolt Biotherapeutics' net margin of -665.56%. Fortress Biotech's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.
Bolt Biotherapeutics presently has a consensus price target of $50.00, indicating a potential upside of 676.40%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 924.39%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.
Summary
Fortress Biotech beats Bolt Biotherapeutics on 15 of the 18 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy FBIO Stock Free FBIO Stock Alerts